Total Funding
54
56
Total FundingSeries B raised
Growth Score
1 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
4587
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.
- Kapil Saxena: Vice President of Clinical DevelopmentPast Role: Autolus, Executive Medical Director
- Jian Irish: President, Chief Executive OfficerPast Role: Kite Pharma, Senior Vice President, Global and Head of Manufacturing
About the Company
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene
editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world.
The company was founded in 2018 and is headquartered in Emeryville, California.
Women Founded
